Michael Grissinger - 28 Jul 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: Director
Signature: /s/ Scott M. Coiante, attorney-in-fact
Issuer symbol: APRE
Transactions as of: 28 Jul 2022
Transactions value $: $0
Form type: 4
Date filed: 01 Aug 2022, 17:02
Previous filing: 26 May 2022
Next filing: 24 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+6K		$0.00	6K	28 Jul 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Option (right to Buy)	Award	$0	+29.6K		$0.00	29.6K	28 Jul 2022	Common Stock	29.6K	$1.09	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2	The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.